Takeda has announced the completion of its 7-year, Phase III TIDES clinical trial (NCT02747927) evaluating the dengue vaccine, Qdenga. Along with an exploratory analysis of a booster dose, TIDES data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback